Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1023/a:1015831201020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Positive findings from testing therapeutics in AD animal models are often not translated to effective treatments due to the poor methodological rigor and inadequate reporting practices of therapeutic efficacy studies. The Alzheimer's Disease Preclinical Efficacy Database (AlzPED), developed by the NIA, is a searchable and publicly available knowledgebase that prioritizes and promotes the use of rigorous methodology to ameliorate this translation gap. Through a checklist of experimental design elements - the Rigor Report Card - AlzPED highlights reporting recommendations and standards while providing a practical tool to help plan rigorous therapeutic studies in animals.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
University of Southern California, San Diego, USA.
Background: Recruitment of demographically diverse participants into Alzheimer's disease (AD) clinical trials, encompassing both screening and randomization, remains a consistent and persistent challenge contributing to underrepresentation of certain groups. Despite the exciting prospects of identifying therapeutic interventions for biomarker-eligible, cognitively unimpaired individuals, these studies grapple with the inherent complexities of AD trials coupled with intricate and time-consuming screening processes. Addressing this the issue of underrepresentation necessitates concerted and intentional efforts that prioritize inclusivity and equitable access to enroll adults meeting study criteria, reflecting the demographic and social diversity of North America.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Neurology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Background: Integrating blood biomarker testing for Alzheimer's Disease (AD) into clinical practice has the potential to transform AD care by enabling broadly accessible and accurate diagnosis, more precise prognostication, and timely initiation of disease-modifying therapy. While there are several scientific challenges to implementing blood biomarkers (e.g.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
University of New South Wales (UNSW), Sydney, NSW, Australia.
Background: Guidelines that provide current and comprehensive overviews of the evidence quality and effectiveness of interventions that address behaviours and psychological symptoms associated with dementia (BPSD, also known as Changed Behaviours) are needed for clinicians, professional care staff and family care partners. With funding provided by the Australian Government Department of Health and Aged Care, we aimed to update the existing Behaviour Management: A Guide to Good Practice, Managing Behavioural and Psychological Symptoms of Dementia (2012) text and app resources to reflect findings from the most recent literature and other sources.
Methods: We systematically searched PubMed, Medline, Embase, and PsycINFO for psychosocial and environmental and biological and pharmacological interventions published between 2012-2021 that addressed BPSD.
Background: Behavioural and psychological symptoms in dementia (BPSD) are common, can be distressing for persons living with dementia (PLWD), and challenging for caregivers and clinicians. There are few updated clinical practice guidelines available to assist clinicians with the assessment and management of BPSD, including deprescribing of medications. The Canadian Coalition for Seniors' Mental Health (CCSMH) developed Canadian clinical practice guidelines on the assessment and management of BPSD to address these needs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!